MX2009008316A - Derivados de indol. - Google Patents

Derivados de indol.

Info

Publication number
MX2009008316A
MX2009008316A MX2009008316A MX2009008316A MX2009008316A MX 2009008316 A MX2009008316 A MX 2009008316A MX 2009008316 A MX2009008316 A MX 2009008316A MX 2009008316 A MX2009008316 A MX 2009008316A MX 2009008316 A MX2009008316 A MX 2009008316A
Authority
MX
Mexico
Prior art keywords
alkyl
pain
alkyloxy
optionally substituted
hydrogen
Prior art date
Application number
MX2009008316A
Other languages
English (en)
Inventor
Julia Adam
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2009008316A publication Critical patent/MX2009008316A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con una derivado de indol que tiene una formula general (1) en donde A representa un anillo heterocíclico aromático de 5 miembros, en donde X1,X2 y X3 son seleccionados de manera independiente de N, O, S y CH;Y representa CH2 O, S o SO2; R1 es H, (C1-4)alquilo, (C1-4)alquiloxi, CN o halógeno; R2, R2', R3, ,R3', R4, R4', R5 y R5' son independientemente hidrógeno, (C1-4)alquilo (opcionalmente substituido con OH)o CO-OR8; o un par de substituyentes germinales R3 y R3' o R5 y R5' que juntos representan un grupo de ceto, y los otros son todos hidrógeno o (C1-4)alquilo; o R2 y R5 juntos representan un puente de metileno o etileno, y R2, R2', R3, R3', R4, R4' y R5' son hidrógeno; n es 1 ó 2; R6 es H, (C1-4)alquilo (opcionalmente substituido con OH, (C1-4)alquiloxi, CO-NR9R10, CO-OR11 ó 1,2,4-oxadiazol-3-il), SO2NR12R13 ó COOR14; R7 es H o halógeno; R8 es (C1-4)alquilo; R9 y R10 son independientemente hidrógeno, (C1-4)alquilo; o (C3-7)cicloalquilo, los grupos de alquilo siendo opcionalmente substituidos con OH o (C1-4)alquiloxi; R11 es H o (C1-4)alquilo; R12 y R13 son independientemente H o (C1-4)alquilo; R14 es (C1-6)alquilo; O una sal farmacéuticamente aceptable del mismo, como agonistas del receptor CB1 canabinoide, el cual puede ser utilizado en el tratamiento de dolor tal como por ejemplo dolor peri-operativo, dolor crónico, dolor neuropático, dolor de cáncer y dolor y espasticidad asociados con esclerosis múltiple.
MX2009008316A 2007-02-22 2008-02-21 Derivados de indol. MX2009008316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102870 2007-02-22
PCT/EP2008/052141 WO2008101995A1 (en) 2007-02-22 2008-02-21 Indole derivatives

Publications (1)

Publication Number Publication Date
MX2009008316A true MX2009008316A (es) 2009-08-12

Family

ID=38283196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008316A MX2009008316A (es) 2007-02-22 2008-02-21 Derivados de indol.

Country Status (18)

Country Link
US (1) US7655645B2 (es)
EP (1) EP2125795B1 (es)
JP (1) JP5324476B2 (es)
KR (1) KR20090113383A (es)
CN (1) CN101616914B (es)
AR (1) AR065393A1 (es)
AU (1) AU2008219226B2 (es)
BR (1) BRPI0807867A2 (es)
CA (1) CA2678147A1 (es)
CL (1) CL2008000514A1 (es)
EC (1) ECSP099593A (es)
IL (1) IL199848A0 (es)
MX (1) MX2009008316A (es)
PE (1) PE20090112A1 (es)
RU (1) RU2009135255A (es)
TW (1) TW200848417A (es)
WO (1) WO2008101995A1 (es)
ZA (1) ZA200905265B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
US7763732B2 (en) * 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
TW200848417A (en) 2007-02-22 2008-12-16 Organon Nv Indole derivatives
JP2012504137A (ja) * 2008-09-29 2012-02-16 アボット・ラボラトリーズ インドール誘導体およびインドリン誘導体ならびにそれらの使用方法
EP2632257B1 (en) 2010-10-25 2021-03-31 Vanderbilt University Compositions for inhibition of insect host sensing
AU2012254032B2 (en) 2011-05-06 2017-02-23 Vanderbilt University Compositions for inhibition of insect sensing
CN102757427A (zh) * 2012-07-09 2012-10-31 陕西科技大学 2-氨基-5-异二氢吲哚-1,3-二酮甲基1,3,4-噻二唑及其制备方法
EP3273779A4 (en) 2015-03-25 2018-09-05 Vanderbilt University Binary compositions as disruptors of orco-mediated odorant sensing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939138A (en) * 1988-12-29 1990-07-03 Sterling Drug Inc. 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
AUPR118000A0 (en) 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
US7772227B2 (en) 2003-12-17 2010-08-10 N.V. Organon Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid CB1 receptor agonists
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
AU2006268680B2 (en) * 2005-07-11 2012-11-22 Msd Oss B.V. Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
TW200745096A (en) 2005-08-23 2007-12-16 Organon Nv Indole derivatives
US7763732B2 (en) * 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
TW200848417A (en) 2007-02-22 2008-12-16 Organon Nv Indole derivatives

Also Published As

Publication number Publication date
US7655645B2 (en) 2010-02-02
EP2125795B1 (en) 2013-03-20
JP5324476B2 (ja) 2013-10-23
PE20090112A1 (es) 2009-02-26
US20080207598A1 (en) 2008-08-28
AU2008219226A1 (en) 2008-08-28
TW200848417A (en) 2008-12-16
RU2009135255A (ru) 2011-03-27
BRPI0807867A2 (pt) 2014-06-03
CN101616914B (zh) 2012-10-10
WO2008101995A1 (en) 2008-08-28
IL199848A0 (en) 2010-04-15
KR20090113383A (ko) 2009-10-30
CN101616914A (zh) 2009-12-30
JP2010519278A (ja) 2010-06-03
ECSP099593A (es) 2009-09-29
EP2125795A1 (en) 2009-12-02
CL2008000514A1 (es) 2008-06-20
AR065393A1 (es) 2009-06-03
ZA200905265B (en) 2010-04-28
CA2678147A1 (en) 2008-08-28
AU2008219226B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
MX2009008316A (es) Derivados de indol.
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
EA201070323A1 (ru) Замещенное производное пиразола
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
MX2007012090A (es) Derivados sustituidos de pirazoliloxifenilo como herbicidas.
GEP20125581B (en) Sulfonyl amide derivatives for treatment of abnormal cell growth
MY146924A (en) Substituted imidazoheterocycles
TW200745034A (en) New compounds
NZ588994A (en) Phenyl and benzodioxinyl substituted indazoles derivatives
EA201070423A1 (ru) Диарильные соединения оксадиазолов
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
MY160942A (en) Melanin production inhibitor
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
EA201070779A1 (ru) Триазолсодержащие производные оксадиазола
EA201000393A1 (ru) Новые соединения как антагонисты аденозинового рецептора а1
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
ZA200810031B (en) 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments
NO20080025L (no) Pyrazolderivater som CB1 modulatorer
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
MX2010009755A (es) Nuevos derivados de triarilo utiles como moduladores de receptores de acetilcolina nicotinicos.
RS20060502A (en) (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
WO2009145357A8 (en) Benzo [1, 4] diazepines substituted at the 1-position by a ring, for use as antidepressants
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration